Abbott Laboratories ($ABT) Stock Forecast: Up 0.8% Today

What is Abbott Laboratories?

Abbott Laboratories is a healthcare company specializing in medical devices, diagnostics, and pharmaceuticals. The stock showed strong bullish movement recently.

Why is Abbott Laboratories going up?

ABT stock is up 0.8% on Jun 1, 2026 15:45

• An accusation related to the termination of a manager supposedly for reporting kickback schemes may have initially led to uncertainty and negative sentiment around Abbott Laboratories.
• The stability in the stock subsequent to recent ETF inclusion and positive analyst outlook with a "Moderate Buy" rating likely contributed to the upward movement.
• The endorsement of Abbott's Cologuard by the American Cancer Society also potentially bolstered investor confidence in the company's potential growth in cancer screening.
• Despite encountering challenges such as pricing pressure in certain markets, Abbott's strategic decisions and product innovations appear to have resonated positively with investors, driving the recent bullish market movement.

ABT Price Chart

ABT Technical Analysis

ABT News

Abbott Accused of Firing Manager for Reporting Kickback Schemes

A former senior district sales manager has accused Abbott Laboratories Inc. of violating the False Claims Act by retaliating against him. Krishnan Ghosh claims he was fired after reporting kickback schemes designed to encourage a medical device customer to make purchases. The complaint, filed in Hawaii, alleges that the termination was retaliatory, despite Abbott's previous attempts to hire Ghosh through competitive negotiations.

https://news.bloomberglaw.com/federal-contracting/abbott-accused-of-firing-manager-for-reporting-kickback-schemes

EBIT per share of Abbott Laboratories Shs UnSponsored Canadian Depository Receipt Hedged – NEO:ABT

This article provides the EBIT per share information for Abbott Laboratories Shs UnSponsored Canadian Depository Receipt Hedged (NEO:ABT). It displays the period, value, change, and percentage change for the EBIT per share. The content itself seems to be a placeholder for financial data provided by TradingView.

https://www.tradingview.com/symbols/NEO-ABT/financials-statistics-and-ratios/ebit-per-share/

Abbott Laboratories stock (US0028241000): U.S. healthcare name steadies after recent ETF inclusion and portfolio moves

Abbott Laboratories' stock (ABT) is stabilizing after its recent inclusion in the Schwab U.S. Dividend Equity ETF (SCHD) and amidst varied institutional investor activity. While SCHD added Abbott due to a reallocation towards healthcare, some institutional investors like the Commonwealth of Pennsylvania Public School Employees’ Retirement System have trimmed their exposure. Analysts maintain a "Moderate Buy" rating with a target price of around $119.09, suggesting a generally constructive outlook despite mixed fund flows.

https://www.ad-hoc-news.de/boerse/news/ueberblick/abbott-laboratories-stock-us0028241000-u-s-healthcare-name-steadies/69457065

Does ACS Endorsement of Cologuard Shape the Bull Case for Abbott Laboratories (ABT) in Cancer Screening?

The American Cancer Society (ACS) recently reaffirmed Abbott's Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options, strengthening Abbott's position in cancer screening. While this endorsement supports Abbott's long-term growth in diagnostics, the company still faces challenges such as stabilizing diagnostics revenue, managing pricing pressure in markets like China, and offsetting declining COVID testing revenue. Abbott's broader investment narrative relies on its ability to convert innovation into steady earnings growth, with new products like Cologuard and Libre Duo glucose sensors playing a key role, but investors should remain aware of potential headwinds like prolonged price pressure from China.

https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/does-acs-endorsement-of-cologuard-shape-the-bull-case-for-ab

Abbott Laboratories stock (US0028241000): Insider activity stays in focus

This article focuses on Abbott Laboratories (US0028241000) and its continued active listing on the NYSE as of May 30, 2026. The main point of interest is the company's ownership structure and director dealings, despite the absence of new insider filings for the specified date. Investors are advised to monitor SEC filings like Form 4 or 13D/13G for any potential changes in insider or block-holder positions.

https://www.ad-hoc-news.de/boerse/news/ueberblick/abbott-laboratories-stock-us0028241000-insider-activity-stays-in-focus/69448249

Trending Today

Chipotle Mexican Grill Inc. ($CMG) Stock Forecast: Down 5.0% Today

CME Group Inc. ($CME) Stock Forecast: Down 5.4% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Up 5.3% Today

Teleflex Incorporated ($TFX) Stock Forecast: Up 2.1% Today

Xerox Corporation ($XRX) Stock Forecast: Down 7.6% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 9.6% Today

Gartner Inc. ($IT) Stock Forecast: Up 5.8% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.3% Today

BlackLine, Inc. ($BL) Stock Forecast: Up 5.2% Today

Equifax Inc. ($EFX) Stock Forecast: Up 5.1% Today

Abbott Laboratories Price History

05.00.2026 - ABT Stock was up 1.3%

• ABT witnessed a significant bullish movement today.
• This trend may be linked to the recent rise in institutional holdings by Asset Management One Co. Ltd., suggesting confidence in the company's performance and future prospects.
• Furthermore, Abbott Laboratories disclosed strong Q3 earnings, increased its quarterly dividend, and garnered a "Moderate Buy" consensus rating from analysts, likely contributing to market optimism and heightened investor interest in the stock.
• The positive institutional investment activity and favorable financial performance indicators have driven ABT's stock price higher today.

16.03.2026 - ABT Stock was down 5.3%

• Strong first-quarter 2026 results were reported by Abbott Laboratories, with net sales up 7.8% year over year and adjusted diluted EPS rising by 6% to $1.15.
• Despite the positive earnings, ABT experienced a bearish movement, falling 3.2% due to concerns over the impact of the recently completed $23 billion acquisition of Exact Sciences on its earnings outlook for 2026.
• The acquisition of Exact Sciences is expected to position Abbott as a leader in the oncology diagnostics market, but the near-term earnings dilution of about $0.20 per share contributed to the stock's decline.
• The struggles in Abbott's nutrition business and the merger costs associated with Exact Sciences were key factors contributing to the bearish movement in ABT's stock price despite the positive earnings beat.

16.03.2026 - ABT Stock was down 5.7%

• ABT stock decreased by 3.2% today, reflecting bearish movement.
• The market's reaction was unfavorable due to Abbott Laboratories revising its 2026 earnings forecast downward, primarily due to the acquisition of Exact Sciences focusing on oncology diagnostics.
• Despite the company meeting expectations for Q1 adjusted EPS and projecting accelerated growth in the latter half of the year, concerns regarding the short-term earnings dilution from the acquisition and challenges in the nutrition sector led to a decline in stock value.
• The costs associated with the acquisition and difficulties in the nutrition division have seemingly outweighed the positive aspects of Abbott's performance, resulting in the stock's downward trend.

22.00.2026 - ABT Stock was down 10.2%

• ABT stock saw a significant decline of 7% post its latest financial results announcement.
• The market responded unfavorably to ABT's sales figure of $11.46 billion, which fell below the analyst forecast of $11.8 billion.
• The market is wary of the impact of the proposed $23 billion acquisition deal with Exact Sciences (EXAS) on ABT's stock performance.
• Though the company's earnings per share for the fourth quarter aligned with analyst predictions, the lower-than-expected sales figures have shaken investor confidence.

22.00.2026 - ABT Stock was down 8.7%

• Abbott Laboratories (ABT) stock plummeted by 7% due to fourth-quarter sales falling short of analyst expectations, despite meeting EPS estimates.
• The pending $23 billion buyout deal with Exact Sciences (EXAS) added uncertainty and pressure on ABT's stock performance.
• The Medical Devices segment showed strong growth with a 12.3% increase in sales, but the overall revenue miss affected the stock negatively.
• The disappointing financial results and underwhelming sales figures are the main drivers behind the bearish movement of Abbott Laboratories' stock today.

22.00.2026 - ABT Stock was down 9.8%

• Abbott Laboratories (ABT) stock experienced a significant bearish movement, dropping 7% in response to its fourth-quarter financial results falling short of analyst expectations.
• The disappointment in sales figures, missing the $11.8 billion estimate, led to a loss in investor confidence and contributed to the stock slump.
• The looming $23 billion buyout deal with Exact Sciences added to the market uncertainty surrounding Abbott's future prospects, further impacting the bearish sentiment.
• Despite meeting EPS estimates and showcasing strong performance in its Medical Devices business with a 12.3% sales increase, the overall revenue miss overshadowed these positive aspects and drove the stock price down.

01.05.2026 - ABT Stock was up 0.8%

• An accusation related to the termination of a manager supposedly for reporting kickback schemes may have initially led to uncertainty and negative sentiment around Abbott Laboratories.
• The stability in the stock subsequent to recent ETF inclusion and positive analyst outlook with a "Moderate Buy" rating likely contributed to the upward movement.
• The endorsement of Abbott's Cologuard by the American Cancer Society also potentially bolstered investor confidence in the company's potential growth in cancer screening.
• Despite encountering challenges such as pricing pressure in certain markets, Abbott's strategic decisions and product innovations appear to have resonated positively with investors, driving the recent bullish market movement.